GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » Cyclically Adjusted Price-to-FCF

THTX (Theratechnologies) Cyclically Adjusted Price-to-FCF : (As of May. 25, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theratechnologies Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Theratechnologies's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Cyclically Adjusted Price-to-FCF Chart

Theratechnologies Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theratechnologies Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theratechnologies's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Theratechnologies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Cyclically Adjusted Price-to-FCF falls into.


;
;

Theratechnologies Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Theratechnologies's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2025 is calculated as:

For example, Theratechnologies's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=-0.394/128.7859*128.7859
=-0.394

Current CPI (Feb. 2025) = 128.7859.

Theratechnologies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201505 0.058 100.263 0.074
201508 0.098 100.579 0.125
201511 0.140 100.421 0.180
201602 0.017 100.421 0.022
201605 -0.059 101.765 -0.075
201608 -0.028 101.686 -0.035
201611 0.118 101.607 0.150
201702 0.109 102.476 0.137
201705 -0.007 103.108 -0.009
201708 -0.084 103.108 -0.105
201711 0.081 103.740 0.101
201802 -0.016 104.688 -0.020
201805 -0.151 105.399 -0.185
201808 0.052 106.031 0.063
201811 0.114 105.478 0.139
201902 0.091 106.268 0.110
201905 -0.574 107.927 -0.685
201908 0.307 108.085 0.366
201911 -0.164 107.769 -0.196
202002 -0.251 108.559 -0.298
202005 -0.646 107.532 -0.774
202008 0.014 108.243 0.017
202011 -0.307 108.796 -0.363
202102 -0.248 109.745 -0.291
202105 -0.033 111.404 -0.038
202108 -0.033 112.668 -0.038
202111 -0.359 113.932 -0.406
202202 -0.241 115.986 -0.268
202205 -0.057 120.016 -0.061
202208 -0.142 120.569 -0.152
202211 -0.218 121.675 -0.231
202302 -0.147 122.070 -0.155
202305 -0.151 124.045 -0.157
202308 0.220 125.389 0.226
202311 -0.171 125.468 -0.176
202402 -0.035 125.468 -0.036
202405 -0.036 127.601 -0.036
202408 0.093 127.838 0.094
202411 -0.005 127.838 -0.005
202502 -0.394 128.786 -0.394

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theratechnologies  (NAS:THTX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Theratechnologies Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies Business Description

Industry
Traded in Other Exchanges
Address
2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.